### 1 **TITLE PAGE**

2



## <sup>28</sup> **Abstract**

29 **Background/purpose**: Excess weight has been identified as a potential risk factor for the 30 development of post-COVID-19 condition (PCC). This review investigates whether 31 excess weight increases the risk of neurological and neuropsychiatric symptoms 32 associated with PCC. **Methods**: Studies published up to July 2023 were searched 33 independently across eight electronic databases to evaluate the risk of developing 34 neurological and neuropsychiatric symptoms more than 12 weeks post-infection between 35 exposure and controls groups (excess weight *vs.* normal weight; obesity *vs.* non-obesity). 36 Meta-analyses were conducted under a random-effects model. **Results:** Of the 10,122 37 abstracts screened, 18 studies (*n* = 139,091 adults) met the inclusion criteria and reported 38 PCC symptoms according to nutritional status. These studies included 79,050 individuals 39 with excess weight *vs* 57,926 normal-weight individuals and 30,694 individuals with 40 obesity *vs* 107,612 non-obese individuals. The presence of excess weight in PCC 41 significantly increased the risk of depression (RR = 1.21; 95% CI: 1.03–1.42), headache 42 (RR = 1.21; 95% CI: 1.09–1.35), memory issues (RR = 1.43; 95% CI: 1.24–1.65), sleep 43 disturbance (RR = 1.31; 95% CI: 1.16–1.48), and vertigo (RR = 1.21; 95% CI: 1.04– 44 1.41). Obesity significantly increased the risk of headache (RR = 1.41; 95% CI: 1.34– 45 1.49), smell disorder (RR = 1.15; 95% CI: 1.09–1.21), taste disorder (RR = 1.21; 95% CI: 46 1.07–1.36), and vertigo (RR = 1.44; 95% CI: 1.35–1.53). **Conclusions:** Excess weight or 47 obesity increases the risk of experiencing neuro-symptoms related to PCC. Individuals 48 with these conditions urgently need enhanced personalized care management in current 49 post-pandemic context.

50 **Keywords:** Post-COVID-19 condition, Neurological symptoms, Neuropsychiatric 51 symptoms, Obesity, Systematic review

## <sup>54</sup> **Introduction**

55 A growing body of evidence suggests that a subset of COVID-19 survivors 56 develop persistent, debilitating symptoms and may face a long road to complete 57 recovery[1–4]. These symptoms have been shown to affect multiple organ systems, as 58 evidenced by respiratory, cardiovascular, neurological, and mental health manifestations. 59 This emergent condition has several names: long-COVID; post-acute sequelae of SARS-60 CoV-2 syndrome; and, as per the World Health Organization (WHO), post-COVID-19 61 condition (PCC). Although PCC has no uniform definition in the literature, it is generally 62 described as involving persistent symptoms or new symptom onset, typically 12 weeks 63 from the acute phase of COVID-19[5, 6], presenting a novel challenge to healthcare 64 systems[7].

65 To date, no comprehensive effective treatment has been recognized for PCC, and 66 the common strategies are based on symptoms relief[8]. Among PCC's range of 67 symptoms, long-term COVID-19 neurological and neuropsychiatric manifestations are of 68 particular interest given the higher incidence of nervous system related sequalae's after 69 post-viral epidemics[9]. Prior reviews revealed that smell and taste disorders, headache, 70 sleep disturbance, anxiety and depression were among the most commonly reported 71 persistent symptoms in the general population. However, these studies only follow 72 participants for a few weeks post-COVID infection and do not meet the criteria for 73 PCC[10–13]. The severity of the COVID-19 acute phase has been associated with the 74 development of long-term COVID-19 neuropsychiatric symptoms[14]. The body mass 75 index (BMI) has been regarded as a potential risk factor for PCC, although the association 76 of excess weight (EW) with the development of specific neurological and 77 neuropsychiatric symptoms remains unclear[15, 16]. Moreover, studies that reported the 78 prevalence of persistent neurological and neuropsychiatric symptoms up to one year after

79 COVID-19 onset exhibited considerable heterogeneity and did not perform subgroups 80 analyses according to nutritional status[2, 17]. An increased number of PCC symptoms 81 that longer persist may be experienced by individuals with EW and might be associated 82 to worsen health and poor quality of life[18].

83 It is noteworthy that EW is a chronic suboptimal heath condition characterized by 84 excessive fat deposits and is considered a global public health problem. It represents a 85 major risk factor for other chronic conditions and encompasses overweight, a suboptimal 86 body weight that represents a risk to health, and obesity, a metabolic disease[19, 20]. A 87 complex yet costly care of individuals with EW is required, with appropriate 88 multidisciplinary, long-term support[19]. In 2020, the overweight and obesity pandemic 89 collided with the COVID-19 pandemic. These conditions' joint negative effects have 90 increased the incidence of related diseases, leading to potentially adverse clinical and 91 social consequences[21–23]. Obesity was found to be associated with poor COVID-19 92 outcomes, such as hospital admissions, intensive care admissions, and lethality rates[24– 93 26]. Although the COVID-19 pandemic has come under control, the multisystemic nature 94 of this disease and its long-term impacts have yet to be elucidated[10, 27].

95 Although there is literature on the most commonly reported neurological and 96 neuropsychiatric symptoms of PCC, few studies reported the risk of PCC symptoms 97 according to nutritional status and no previous review has explored the association of EW 98 and the risk of developing specific neurological or neuropsychiatric symptoms among 99 COVID-19 survivors. Elucidating the long-term neuro-outcomes of COVID-19, along 100 with its suite of symptoms and high-risk populations, is urgently needed to facilitate the 101 development of reliable and personalized care management strategies. Therefore, this 102 systematic review addresses whether EW increases the risk of developing specific 103 persistent neurological or neuropsychiatric symptoms among COVID-19 survivors.

## <sup>104</sup> **Materials and Methods**

105 This study followed the Preferred Reporting Items for Systematic Reviews and 106 Meta-Analyses (PRISMA) 2020 guidelines[28]. It is a subset of broad research aimed at 107 investigating the role of EW in the development of persistent symptoms of PCC. This 108 review was registered at the International Prospective Register of Systematic Reviews 109 (PROSPERO) (ID: CRD42023433234).

## 110 **Search strategy and Eligibility Criteria**

111 Two authors (DBR and LOM) searched seven electronic databases (MEDLINE, 112 EMBASE, SCOPUS, Web of Science, VHL, Google Scholar, ProQuest) and a preprint 113 server (medRxiv) on 3 July 2023. The search strategy was reviewed by two reviewers 114 according to the criteria of the Peer Review of Electronic Search Strategies (PRESS) 115 checklist[29]. The search strategy included the following terms: ("long COVID-19" OR 116 "post-acute covid 19 syndrome" OR "COVID-19" OR "SARS-CoV-2" OR "post-117 COVID-19 condition" OR "long hauler") AND ("excess of weight" OR "overweight" 118 OR "obesity" OR "body mass index") AND ("signs and symptoms" OR "COVID-19 119 sequelae" OR "headache" OR "loss of smell" OR "cognitive dysfunction" OR "anxiety" 120 OR "depression" OR "sleep disorder" OR "brain fog)." The full search strategy is detailed 121 in supporting information (S1 Table). Additionally, some articles were hand-searched to 122 identify potentially eligible studies which might not be electronically retrieved, including 123 those published in 2024.

124 Studies were considered eligible for inclusion if they (a) had observational 125 designs; (b) primarily focused on adults; (c) classified focal populations based on the 126 presence of excess weight/obesity *versus* normal weight/non-obesity, using either 127 measured BMI or self-reported data; and (d) had a mean (or median) follow-up of at least 128 12 weeks after the acute phase of COVID-19. Survivors could be (a) hospitalized or non-

129 hospitalized, (b) inpatient or outpatient, and (c) mixed population (hospitalized and 130 outpatient) recruited in the community, outpatient clinic or heath care system.

131 We exclude editorials, clinical trials, reviews, opinions, books or book chapters, 132 conference abstracts, case reports, and correspondence articles. Studies were also 133 excluded if they included mostly pregnant or nursing women; evaluated the health effects 134 of COVID-19; assessed excess weight as a risk factor for acute-phase severity or 135 mortality; or evaluated long-term sequelae of COVID-19 in a specific population (e.g., 136 individuals with specific comorbidities). Additionally, studies were excluded if they 137 investigated clusters of symptoms rather than specific symptoms or if they lacked a 138 control group (i.e., COVID-19 survivors who did not report persistent symptoms).

## 139 **Screening Process, Study Selection, and Data Extraction**

140 The same two authors (DBR and LOM) independently screened the titles and 141 abstracts of studies obtained from database searches and removed duplicates. The Rayyan 142 app[30], a semi-automation tool, was used to streamline the review process. This was 143 followed by a full-text review of the retained articles to ensure they met eligibility criteria. 144 Fig 1 presents the flowchart for the included studies.

145

### 146 **Fig 1: Flow diagram of included studies.**

147

148 The study population of interest comprised COVID-19 survivors. Exposure was 149 defined as EW or obesity based on BMI measurement, data from electronic medical 150 records, or self-reported information. Two exposure groups were defined according to 151 WHO guidelines [31]: 1) an excess weight group (BMI  $\geq$ 25 kg/m<sup>2</sup>) and 2) an obesity 152 group (BMI ≥30 kg/m<sup>2</sup> ). Both Asian and Caucasian populations were included in the 153 analysis, with corresponding BMI cut-offs applied: for Asian-Pacific populations, the

154 thresholds were BMI  $\geq$ 23 kg/m<sup>2</sup> for EW and BMI  $\geq$ 25 kg/m<sup>2</sup> for obesity, as previously 155 defined in the included studies[32, 33].

156 We adopted WHO's definition of PCC as outlined by Soriano *et al*. (2021)[5]. 157 Symptoms were measured with predefined questionnaires/scales or reported during 158 interviews (in person, by phone, or online). Due to varying definitions illness onset 159 (baseline), we accepted definitions that included 12 weeks from the onset of COVID-19 160 symptoms, COVID-19 diagnosis, hospital admission or discharge after the acute phase. 161 For the follow-up period, we considered studies where the sample median (or mean) of 162 persistent symptoms was reported at least 12 weeks (84 days) after the baseline, with a 163 minimum interquartile range (IQR) of 10 weeks (or a standard deviation (SD) of  $\pm 24$ 164 days) from baseline. This cut-off was necessary to include studies evaluating long-term 165 sequelae of COVID-19. Given the varied terminology used for symptoms across studies, 166 we re-grouped symptoms into neurological and neuropsychiatric categories as shown in

167 Fig 2.

168

## 169 **Fig 2: Reported neurological and neuropsychiatric symptoms related to Post-**

170 **COVID-19 condition (PCC).** <sup>a</sup>Neurological and neuropsychiatric reported symptoms were grouped 171 into one category with synonyms presented in brackets.

172

173 Specific data were exported from each study into a predefined data collection 174 form, including authors; publication year; country; aim of the study; study design; mean 175 follow-up period; study population; exposure groups; assessment of outcome; evaluated 176 symptoms; frequency of symptoms (*n*, %) among exposure and control groups; and the 177 effect measure of the association of EW and the neurological/neuropsychiatric symptom. 178 Corresponding authors of relevant articles published were contacted if any data were 179 absent.

## 180 **Quality Assessment**

181 The ROBINS-E tool for observational research was used to determine the risk of 182 bias in the included studies[34]. ROBINS-E is a domain-based tool that evaluates seven 183 domains (confounders, exposure measurement, participant selection, post-exposure 184 interventions, missing data, outcome measurement, and selection of reported results) and 185 then a general assessment of the study. Traffic plots with a final analysis of studies' risk 186 of bias, by domain, is generated. For this research, two authors (DBR and DO) initially 187 appraised the risk of bias. Disagreements were discussed and resolved in collaboration 188 with a third researcher (LOM). The ROBINS-E tool was not applied as a study eligibility 189 criterion.

190 We assessed the certainty of evidence via the Grading of Recommendations 191 Assessment, Development and Evaluation (GRADE) framework [35–37] regarding the 192 risk of developing PCC-related neurological and neuropsychiatric symptoms among 193 individuals with EW. The GRADE system measures attributes that impact the overall 194 quality of evidence. We assessed the certainty of evidence of the outcomes that were 195 statistically significantly associated with exposures groups and scored it accordingly (i.e., 196 high =  $\geq$ 4 points; moderate = 3 points; low = 2 points; very low = 1 point).

197 **Statistical Analysis**

198 The frequency of reported symptoms and the associated risk of development were 199 determined for EW *vs* normal weight groups and for obesity *vs* non-obesity groups, 200 classified by BMI when available (normal weight: BMI of 18–24.9 kg/m<sup>2</sup>; excess weight: 201 BMI > 25 kg/m<sup>2</sup>; obesity: BMI > 30 kg/m<sup>2</sup>; non-obesity group: BMI < 30 kg/m<sup>2</sup>), taking 202 into account different cut-off values previously defined for the Chinese population in 203 studies[32, 33]. Each symptom was considered an individual outcome. For this purpose, 204 we collected data of the frequency (*n*, %) of each neurological and neuropsychiatric

205 symptoms related to PCC reported and the risk of developing persistent symptoms (as 206 measured by the odds ratio [OR] or the adjusted OR) at follow-up in included studies.

207 We performed meta-analytic calculations using STATA software (SE/17). Pooled 208 risk ratios (RRs) with their 95% confidence intervals (CIs) were computed from the raw 209 data of the included studies. A random effects model meta-analysis was conducted to 210 account for the statistical and methodological heterogeneity of the data. We used a two-211 sample binary-outcome summary dataset format with DerSimonian–Laird estimation 212 when fewer than five studies were available[38]; when more than five studies were 213 available, we adopted restricted maximum-likelihood estimation and to conduct pooled 214 RR analysis. Statistical heterogeneity was assessed using the  *statistic<sup>[39]</sup>. Forest plots* 215 were generated for all outcomes. Publication bias was examined by visual inspection of 216 funnel plots. A value of *p* < 0.05 was considered statistically significant.

217

## <sup>218</sup> **Results**

219 Of the 10,122 abstracts screened, 211 full-text registers were reviewed, and 65 220 studies were considered eligible. Data on neurological and neuropsychiatric symptoms 221 according to individuals' nutritional status were available for 18 studies (including one 222 preprint[40]), all of which were entered into our meta-analysis.

223 Selected studies originated from 23 countries across Asia (China[32, 33], 224 India[41], Indonesia[42], Japan[43], Malaysia[40] and Saudi Arabia[44]), Europe 225 (Denmark[45, 46], England[47], Germany[48], Italy[49], Poland[50], Spain[51] and 226 Switzerland[52]), and North and South America (Argentina[53], Brazil[53], Chile[53], 227 Dominican Republic[53], Ecuador[53], Mexico[53], Panama[53], Paraguay[53], 228 Peru[53] and United States of America[54, 55]), comprising both developed and 229 developing countries. Among the included studies, two employed case–control design[51,

230 54], six involved retrospective or prospective cohorts[33, 42, 49, 50, 52, 55], and 10

231 involved cross-sectional studies[32, 40, 41, 44–47, 47, 48, 53].

232 The populations investigated varied: three studies evaluated individuals in 233 outpatient settings[46, 52, 54], five involved hospitalized patients[32, 33, 42, 49, 51] , 234 and ten included individuals either hospitalized or outpatient settings during COVID-19 235 acute-phase[40, 41, 43, 44, 47, 48, 50, 53, 55]. The classification of individuals according 236 to nutritional status also varied: four studies compared symptoms between individuals 237 with EW and those with normal weight[32, 40, 42, 44], five studies evaluated obesity 238 *versus* non-obesity[33, 48–51], eight studies presented data for individuals with normal 239 weight, overweight and obesity[41, 45–47, 52–55], and one study only provided the mean 240 BMI of the sample without specifying the number of individuals in exposure and control 241 groups[43]. In total, our meta-analysis included 79,050 people with EW and 30,694 with 242 obesity in exposure groups, while 57,926 normal weight individuals and 107,612 non-243 obese individuals comprised control groups. Sample sizes ranged from 32[54] to 244 78,566[47] COVID-19 survivors. Two Chinese studies applied different cut-off points for 245 nutritional status classification (EW as BMI  $\geq$ 23 kg/m<sup>2</sup>; obesity as BMI  $\geq$ 25 kg/m<sup>2</sup>)[32, 246 33]. Exposure was assessed via anthropometric measures[32, 33, 41, 50, 53, 54], 247 electronic medical record data[42, 46, 49, 51], and self-reported comorbidity/BMI[40, 248 43–45, 47, 52, 55]. PCC neurological and neuropsychiatric symptoms were evaluated 249 using questionnaires[33, 41, 43–47, 50–52, 54], validated scales[32, 40, 48, 49, 51, 54], 250 or self-report instruments[42, 47, 48, 53, 55]. The mean time from COVID-19 onset 251 (baseline) to long-term symptom assessment was 25.8 weeks (range: 12 weeks[42, 44, 252 46, 47, 49] to 52 weeks [one year][32]). Table 1 outlines the features of the included 253 articles.

255 **Table 1. Characteristics of included studies.**

















**Table 2. Frequency of neuropsychiatric symptoms related to post-COVID condition and the risk of their development in included studies.**



\*Statistically significant; NA: non-available information; excess-weight group (BMI ≥25 kg/m<sup>2</sup>); normal-weight group (BMI <25 kg/m<sup>2</sup>); obesity group (BMI ≥30 kg/m<sup>2</sup>); non-obesity group (BMI <30 kg/m<sup>2</sup>). <sup>a</sup>Different cut-off values were used to define excess weight and obesity in Asian populations (excess weight ≥ 23kg/m<sup>2</sup>; obesity ≥25  $kg/m<sup>2</sup>$ ).

## 293 **Excess Weight and the Risk of Neuropsychiatric Symptoms**



313 evaluated symptoms (S2 Fig 2).

## 314 **Obesity and the Risk of Neuropsychiatric Symptoms**

315 Our pooled risk analysis for obesity and neurological and neuropsychiatric 316 symptoms (Figs 4a and 4b) showed that individuals with obesity are at significantly

317 higher risk than those with normal weight or overweight (non-obesity control group) for 318 a range of neurological symptoms: headache (RR = 1.41; 95% CI: 1.34–1.49;  $I^2 = 3.39$ ); 319 numbness (RR = 1.61; 95% CI: 1.46–1.78;  $I^2 = 0.00$ ); smell disorder (RR = 1.15; 95% 320 CI: 1.09–1.21;  $I^2 = 7.55$ ); taste disorder (RR = 1.21; 95% CI: 1.07–1.36;  $I^2 = 63.57$ ); and 321 vertigo (RR = 1.44; 95% CI: 1.35–1.53;  $I^2 = 0.00$ ). No statistically significant association 322 was found between obesity and the risk of developing PCC-related neuropsychiatric 323 symptoms (S1 Fig 1b).

324

325 **Fig 4a. Forest plot of obesity and risk ratio (RR) for neurological and**  326 neuropsychiatric symptoms. a Applied a different BMI cut-off (obesity >25 kg/m<sup>2</sup>).

327 **Fig 4b. Forest plot of obesity and risk ratio (RR) for neurological and**  328 **neuropsychiatric symptoms (continuation)**

329

330 Substantial heterogeneity was observed in our meta-analysis for the non-331 significant association of obesity and anxiety ( $I^2 = 70.5\%$ ) and sleep disorder ( $I^2 =$ 332 61.94%) as well as for the statistically significant association between obesity and taste 333 disorder  $(I^2 = 69.5\%)$ . Meanwhile, no statistically significant heterogeneity was observed 334 in other analyses where obesity was the exposure condition. Subgroup analyses could not 335 be performed due to an insufficient number of studies evaluating the same outcome 336 according to nutritional status.

## 337 **Risk-of-bias Assessment and Publication Bias**

338 We assessed the risk of bias for each effect measure (frequency and OR). Results 339 for studies reporting the frequency of PCC symptoms are presented in Fig 5; while 340 findings for studies reporting OR are displayed in Supporting Information (S3 Fig 3). 341 Among the 18 studies evaluated, seven were judged to have a high risk of bias due to self-



### **Table 3. Assessment of the overall certainty of the evidence.**

ed studies



suspected<sup>b</sup>

 $(2.4\%)$ 

 $(1.8\%)$ 

1.51)

more)

Lowa,b



#### **Vertigo (follow-up: range 12 to 38 weeks; assessed with: Questionnaire and self-reported)**



**CI:** confidence interval; **RR:** risk ratio; a. The risk of bias of included studies is related to measurement of exposure (self-reported) or confounders control, especially regarding severity of COVID-19 acute phase; b. There are less than 10 studies included in the meta-analysis therefore we were unable to evaluate publication bias; c. Meta-analysis showed moderate heterogeneity among included studies  $(I^2 = 41\%)$ ; d. The quality of evidence was downgraded from high due to the high risk of bias of included studies; e. Meta-analysis showed moderate heterogeneity among included studies ( $I^2 = 53\%)$ ; f. Meta-analysis showed moderate heterogeneity among included studies ( $I^2 = 59.5\%$ ).

## <sup>364</sup> **Discussion**

365 Although it has been suggested that individuals with increased BMI are at higher 366 risk of PCC, the associations between EW and specific PCC related neurological and 367 neuropsychiatric symptoms remained unclear. Our review reveals that EW is significantly 368 associated with a range of persistent and PCC symptoms, including headache, vertigo, 369 smell and taste disorder, sleep disturbance and depression. These findings suggest that 370 EW markedly increases the risk of developing these symptoms that persist for more than 371 12 weeks after COVID-19 onset. Moreover, this study is opportune as we transition into 372 the post-pandemic period facing the challenges of managing the co-occurrence of 373 pandemics, including overweight/obesity, mental health issues, and the burden of PCC.

374 Increased BMI has been identified as a determinant of adverse outcomes during 375 both the acute and chronic phases of COVID-19[16, 24, 26]. This contrasts with the role 376 of sex in the disease course since the pattern of acute phase symptoms by sex is distinct 377 from that of PCC, which tends to affect more females[18, 56]. Additionally, the chronic 378 phase of COVID-19's has been variously defined, with some studies indicating symptoms 379 lasting for at least 4 weeks[10] and others extending to more than 12 weeks[5, 6]. 380 Differentiating these time frames is crucial to distinguish between acute illness and 381 potential sequelae of irreversible tissue damage, which may present with varying degrees 382 of impairment[57]. In our review, we used the cut-off criterion to ensure that we focused 383 on long-term or chronic outcomes of COVID-19. The mean follow-up time from illness 384 onset in the included studies was 25.8 weeks (ranging from 12 to 52 weeks). A large 385 systematic review[2] evaluated the prevalence of persistent symptoms among COVID-19 386 survivors at different follow-up periods. It identified sleep disorder and concentration 387 difficulties as the most common symptoms at 3–6 months (24%, 95% CI: 8%–44%; 22%, 388 95% CI: 15%–31%, respectively), with sleep disorder being most prevalent at over 12

389 months. However, unlike our results, this review had a high degree of between-study 390 heterogeneity and did not include BMI in subgroups analysis.

391 Long-term neurological symptoms significantly decrease the quality of life for 392 individuals, a situation that might be exacerbated by a pre-exiting comorbidities[58]. 393 Moreover, symptoms related to comorbidities often overlap with those of PCC, leading 394 individuals with obesity to attribute their symptoms to their metabolic disease rather than 395 to persistent manifestations of COVID-19[59, 60]. Additionally, overweight individuals 396 also report health complaints, including headache and sleeplessness, associated to their 397 subclinical disease state also known as suboptimal health status, which can be exacerbated 398 by PCC symptoms[20]. The co-occurrence of these complex conditions can have 399 deleterious effects, impairing people's daily functioning and increasing the demand on 400 healthcare systems. Our results highlight a significantly increased risk for persistent 401 headache, vertigo, numbness and taste disorder in individuals with EW or obesity. This 402 underscores the role of excessive body weight (fat deposits) in PCC. It is worth noting 403 that patients with PCC have reported that head pain worsens with physical exercise while 404 a decrease in physical activity coupled with increase in sedentary behaviour are generally 405 known to contribute to weight gain[61], [62]. Moreover, taste disorders may influence 406 unhealthy weight-related behaviours, such as consuming more palatable, ultra-processed 407 foods high in salt, sugar, and additives. These foods can further impair gustatory function 408 and exacerbate unhealthy symptoms[63, 64]. Vertigo which impairs daily functioning by 409 increasing the risk of falls may also be associated with depression[65, 66]. Therefore, 410 healthcare systems and public policies should focus on multidisciplinary rehabilitation 411 services to address the long-term impacts of COVID-19 on survivors, specifically through 412 concomitant personalized management of weight, neurological and neuropsychiatric 413 issues.

414 The high prevalence of persistent complex concurrent symptoms may create a 415 vicious circle between physical and neuropsychiatric symptoms, increasing the risk for 416 depression[67–70]. A significant positive association between obesity and depressed 417 mood has been observed across multiple COVID-19 periods, similar to findings in other 418 coronavirus outbreaks[9, 14, 62]. During the COVID-19 pandemic, a systematic review 419 of longitudinal studies identified obesity/overweight as a risk factor for depression 420 (pooled RR = 1.2; 95% CI: 1.11-1.31). However, no significant association was found 421 when obesity/overweight was self-reported (pooled RR = 1.03; 95% CI: 0.99–1.26)[71]. 422 In this study, we observed a heightened risk of persistent depression among individuals 423 with EW compared with those with normal weight. This findings aligns with Aminian *et*  424 *al.*[72] who reported that the need for diagnostic test to assess neuropsychiatric problems 425 (a *proxy* for symptoms) was significantly higher in individuals with increased BMI 426 compared to those with normal weight. Although our pooled RR for EW and depression 427 included data from two studies conducted with Asian populations[32, 40] featuring 428 different BMI assessments (measured and self-reported) and BMI cut-offs (excess weight 429 defined as BMI  $\geq$  23kg/m<sup>2</sup> and obesity as BMI  $\geq$  25 kg/m<sup>2</sup>), both studies used a validated 430 depression scale (PHQ-9), and the results were not heterogeneous.

431 It remains uncertain whether neurological and neuropsychiatric manifestations 432 related to PCC are directly attributable to the virus itself or if they develop indirectly 433 (such as, through an immune response or medical therapy). These symptoms may also 434 involve both the central and peripheral nervous systems[14]. Additionally, the role of EW 435 in the progression of COVID-19 is not fully understood, though it may be linked to an 436 exaggerated inflammatory response or shared pre-existing genetic factors that these 437 conditions share[73–75]. EW is also a recognized risk factor for various chronic 438 conditions and the number of pre-existing comorbidities has been associated to the

439 development of PCC symptoms up to two years after COVID-19 onset, in both 440 hospitalized and non-hospitalized patients[76]. Our results underscore the importance of 441 identifying at-risk individuals and highlight the need for timely personalized interventions 442 for COVID-19 survivors. These findings could inform the development of predictive and 443 preventive management plans for future waves of SARS-CoV-2 or other epidemics.

444 Our quality assessment results indicate that the included studies suffer from 445 methodological issues, particularly in measuring exposure. Studies that classified 446 individuals' nutritional status based on self-reported data were found to have a high risk 447 of bias, which contributed to downgrade in the overall quality of evidence of evaluated 448 for the evaluated symptoms. During the height of the pandemic, online health surveys 449 were often used when other research methods were infeasible[77]. However, significant 450 issues can also arise from self-reported symptoms in studies that did not employ 451 structured questionnaire or validated scales. Although screening tools have been proposed 452 to identify people with PCC they often do not consider neuropsychiatric symptoms[78] 453 or important cognitive symptoms[79] that significantly affect individuals' quality of life. 454 The observed moderate heterogeneity among studies evaluating headache, taste disorder 455 and vertigo has led to imprecision in the results and the limited number of studies included 456 in meta-analysis unable the assessment of publication bias, further contributing to 457 downgrade of the overall quality of evidence for those outcomes from high to very low.

458 It is important to acknowledge certain limitations when interpreting the findings 459 of our research. Most of the included studies were cross-sectional which limits the ability 460 to determine cause and effect relationships. The inconsistency in naming PCC symptoms 461 among studies resulted in a relatively low number of studies reporting the same symptom 462 which also precluded subgroup comparisons between hospitalized and outpatient 463 populations. We included studies that used non-validated questionnaires to assess

464 symptoms, as it was necessary given that PCC is an emerging condition and validated 465 screening tools have yet to be developed. Although the cut-off for study inclusion 466 regarding time to follow-up (i.e., >12 weeks) allowed us to track long-term outcomes 467 from COVID-19 and address a gap in the literature, the follow-up period ranged from 12 468 to 52 weeks post-infection, the varying risk of PCC symptoms throughout different 469 follow-up periods was not investigated in subgroup analysis due to limited number of 470 studies. Additionally, the inclusion of both obesity and non-obesity as comparisons 471 groups led to the interchange of overweight individuals between exposure and control 472 groups. Nevertheless, defining EW and obesity as exposure groups was crucial given the 473 syndemic context. This approach enabled the evaluation of the risk of developing 474 persistent symptoms among different levels of excessive fat and highlighted that both 475 suboptimal health status (overweight) and illness (obesity) predisposed individuals to 476 PCC-related neuro-symptoms. However, the inherent differences among these groups 477 should be considered in health, disease prevention and diagnoses. Furthermore, the issues 478 related to body fat assessment should be noted as BMI remains the most widely used 479 screening tool for measuring adiposity. Although it is a simple and non-invasive measure 480 often related to the gold standard fat assessment BMI does not accounts for the types or 481 distribution of adipose tissue, nor does it for age and ethnic backgrounds[80]. Future 482 research should focus on longitudinal evaluation of COVID-19 survivors incorporating 483 objective assessment of symptoms and adiposity.

484 Despite these limitations, our review has several scientific and clinical strengths. 485 Notably, the number of investigated outcomes allowed for a pioneering evaluation of the 486 association of EW with both the physical and psychological long-term manifestations of 487 COVID-19. Additionally, the comprehensive definition of PCC that we applied during 488 our article search (to account for varied terminology), along with the inclusion of each

489 neurological and neuropsychiatric symptom specified in our search strategy, ensured a 490 thorough screening process. We also underscored the importance of addressing EW as a 491 global health concern, given its interplay with neurological and neuropsychiatric 492 manifestations, and infectious diseases such as COVID-19. The management of EW 493 should be considered in the treatment of neurological and neuropsychiatric symptoms due 494 to the significant impact that these combined conditions have on individuals' health.

495

## <sup>496</sup> **Conclusions**

497 Our systematic review and meta-analysis demonstrate that EW is significantly 498 associated with an increased risk of developing post-COVID-19 neurological and 499 neuropsychiatric symptoms, including headache, memory issues, numbness, smell and 500 taste disorders, vertigo, depression, and sleep disturbance. These findings underscore the 501 need for developing multidisciplinary rehabilitative strategies tailored to individual needs 502 to improve care management and support the overall health of affected individuals. Our 503 results provide evidence-based guidance for healthcare professionals and policymakers 504 in managing PCC, and further support ongoing global efforts to understand its underlying 505 mechanisms, epidemiology, and identification.

506

## <sup>507</sup> **Acknowledgements:**

508 We would like to thank the researchers who shared information and enabled more precise 509 results in this study. We would also like to acknowledge students and collaborators of the 510 PENSA research group at the University of Brasília and the Centre for Precision Health 511 at Edith Cowan University for their support.

## <sup>513</sup> **References**

- 514 [1] Blumenthal D, Fowler EJ, Abrams M, Collins SR. Covid-19 Implications for 515 the Health Care System. *N Engl J Med* 2020; 383: 1483–1488.
- 516 [2] Alkodaymi MS, Omrani OA, Fawzy NA, Shaar BA, Almamlouk R, Riaz M, et al. 517 Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up 518 periods: a systematic review and meta-analysis. *Clin Microbiol Infect* 2022; 28: 519 657–666.
- 520 [3] Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. 521 Post-acute COVID-19 syndrome. *Nat Med* 2021; 27: 601–615.
- 522 [4] Carfì A, Bernabei R, Landi F. Persistent Symptoms in Patients After Acute 523 COVID-19. *JAMA* 2020; 324: 603–605.
- 524 [5] WHO. A clinical case definition of post-COVID-19 condition by a Delphi 525 consensus - The Lancet Infectious Diseases, 526 https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00703- 527 9/fulltext (accessed 15 October 2023).
- 528 [6] NICE NI for H and C of E. 1 Identification | COVID-19 rapid guideline: managing 529 the long-term effects of COVID-19 | Guidance | NICE, 530 https://www.nice.org.uk/guidance/ng188/chapter/1-Identification (2020, accessed 531 20 June 2024).
- 532 [7] Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-533 acute covid-19 in primary care. *BMJ* 2020; 370: m3026.
- 534 [8] Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, 535 mechanisms and recommendations. *Nat Rev Microbiol* 2023; 21: 133–146.
- 536 [9] Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, et al. 537 Psychiatric and neuropsychiatric presentations associated with severe coronavirus 538 infections: a systematic review and meta-analysis with comparison to the COVID-539 19 pandemic. *Lancet Psychiatry* 2020; 7: 611–627.
- 540 [10] Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute 541 sequelae of COVID-19. *Nature* 2021; 594: 259–264.
- 542 [11] Fanshawe JB, Sargent BF, Badenoch JB, Saini A, Watson CJ, Pokrovskaya A, et 543 al. Cognitive domains affected post-COVID-19; a systematic review and meta-544 analysis. *Eur J Neurol*; n/a: e16181.
- 545 [12] Badenoch JB, Rengasamy ER, Watson C, Jansen K, Chakraborty S, Sundaram RD, 546 et al. Persistent neuropsychiatric symptoms after COVID-19: a systematic review 547 and meta-analysis. *Brain Commun* 2022; 4: fcab297.
- 548 [13] Malik P, Patel K, Pinto C, Jaiswal R, Tirupathi R, Pillai S, et al. Post‐acute 549 COVID-19 syndrome (PCS) and health-related quality of life (HRQoL)—A 550 systematic review and meta‐analysis. *J Med Virol* 2022; 94: 253–262.

- 551 [14] Pilotto A, Cristillo V, Cotti Piccinelli S, Zoppi N, Bonzi G, Sattin D, et al. Long-552 term neurological manifestations of COVID-19: prevalence and predictive factors. 553 *Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol* 2021; 42: 4903–4907.
- 554 [15] Luo D, Mei B, Wang P, Li X, Chen X, Wei G, et al. Prevalence and risk factors for 555 persistent symptoms after COVID-19: a systematic review and meta-analysis. *Clin*  556 *Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis* 2024; 30: 328–335.
- 557 [16] Tsampasian V, Elghazaly H, Chattopadhyay R, Debski M, Naing TKP, Garg P, et 558 al. Risk Factors Associated With Post−COVID-19 Condition: A Systematic 559 Review and Meta-analysis. *JAMA Intern Med* 2023; 183: 566–580.
- 560 [17] Ceban F, Ling S, Lui LMW, Lee Y, Gill H, Teopiz KM, et al. Fatigue and cognitive 561 impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. 562 *Brain Behav Immun* 2022; 101: 93–135.
- 563 [18] Notarte KI, de Oliveira MHS, Peligro PJ, Velasco JV, Macaranas I, Ver AT, et al. 564 Age, Sex and Previous Comorbidities as Risk Factors Not Associated with SARS-565 CoV-2 Infection for Long COVID-19: A Systematic Review and Meta-Analysis. *J*  566 *Clin Med* 2022; 11: 7314.
- 567 [19] Bray G a., Kim K k., Wilding J p. h., Federation on behalf of the WO. Obesity: a 568 chronic relapsing progressive disease process. A position statement of the World 569 Obesity Federation. *Obes Rev* 2017; 18: 715–723.
- 570 [20] Mahara G, Tan X, Wang W. Risk Factors, Health Status, and Risk Groups in 571 Suboptimal Health Condition. In: Wang W (ed) *All Around Suboptimal Health :* 572 *Advanced Approaches by Predictive, Preventive and Personalised Medicine for*  573 *Healthy Populations*. Cham: Springer Nature Switzerland, pp. 61–72.
- 574 [21] Hepatology TLG&. Obesity: another ongoing pandemic. *Lancet Gastroenterol*  575 *Hepatol* 2021; 6: 411.
- 576 [22] Lockhart SM, O'Rahilly S. When Two Pandemics Meet: Why Is Obesity 577 Associated with Increased COVID-19 Mortality? *Med N Y N* 2020; 1: 33–42.
- 578 [23] Swinburn BA, Kraak VI, Allender S, Atkins VJ, Baker PI, Bogard JR, et al. The 579 Global Syndemic of Obesity, Undernutrition, and Climate Change: The Lancet 580 Commission report. *Lancet Lond Engl* 2019; 393: 791–846.
- 581 [24] Nagar M, Geevarughese NM, Mishra R, Joshi A, Galwankar S, Yunus M, et al. 582 Body-mass index COVID-19 severity: A systematic review of systematic reviews. 583 *J Fam Med Prim Care* 2022; 11: 5351–5360.
- 584 [25] Armstrong RA, Kane AD, Cook TM. Outcomes from intensive care in patients 585 with COVID-19: a systematic review and meta-analysis of observational studies. 586 *Anaesthesia* 2020; 75: 1340–1349.
- 587 [26] Chen Z, Peng Y, Wu X, Pang B, Yang F, Zheng W, et al. Comorbidities and 588 complications of COVID-19 associated with disease severity, progression, and 589 mortality in China with centralized isolation and hospitalization: A systematic 590 review and meta-analysis. *Front Public Health* 2022; 10: 923485.

- It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .
- 591 [27] Staffolani S, Iencinella V, Cimatti M, Tavio M. Long COVID-19 syndrome as a 592 fourth phase of SARS-CoV-2 infection. *Infez Med* 2022; 30: 22–29.
- 593 [28] Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. 594 The PRISMA 2020 statement: an updated guideline for reporting systematic 595 reviews. *The BMJ* 2021; 372: n71.
- 596 [29] McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS 597 Peer Review of Electronic Search Strategies: 2015 Guideline Statement. *J Clin*  598 *Epidemiol* 2016; 75: 40–46.
- 599 [30] Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and 600 mobile app for systematic reviews. *Syst Rev* 2016; 5: 210.
- 601 [31] WHO Consultation on Obesity (1999: Geneva S, Organization WH. *Obesity :* 602 *preventing and managing the global epidemic : report of a WHO consultation*. 603 World Health Organization, https://iris.who.int/handle/10665/42330 (2000, 604 accessed 12 June 2024).
- 605 [32] Li Z, He J, Wang Y, Bai M, Zhang Y, Chen H, et al. A cross-sectional study on the 606 mental health of patients with COVID-19 1 year after discharge in Huanggang, 607 China. *Eur Arch Psychiatry Clin Neurosci* 2023; 273: 301–310.
- 608 [33] Shang L, Wang L, Zhou F, Li J, Liu Y, Yang S. Long-term effects of obesity on 609 COVID-19 patients discharged from hospital. *Immun Inflamm Dis* 2021; 9: 1678– 610 1685.
- 611 [34] Higgins JPT, Morgan RL, Rooney AA, Taylor KW, Thayer KA, Silva RA, et al. 612 A tool to assess risk of bias in non-randomized follow-up studies of exposure 613 effects (ROBINS-E). *Environ Int* 2024; 186: 108602.
- 614 [35] Ryan R, Hill S. How to GRADE the quality of the evidence. Cochrane Consumers 615 and Communication Group,. *Cochrane. Consumers and Communication*, 616 https://cccrg.cochrane.org/author-resources (2016, accessed 8 November 2023).
- 617 [36] Schünemann HJ, Brożek J, Guyatt G, Oxman A. GRADE handbook, 618 https://gdt.gradepro.org/app/handbook/handbook.html#h.h2a1ln3pqdrc (accessed 619 18 June 2024).
- 620 [37] Guideline Development Tool, 621 https://gdt.gradepro.org/app/#projects/p\_l\_deboraronca\_gmail\_com\_0\_1bcf9a94- 622 38f9-4870-ad7d-f19f0205fadc/evidence-syntheses/395b01fd-9923-48a0-81e7- 623 cf4c69f477d2/quality-of-evidence (accessed 18 June 2024).
- 624 [38] DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986; 625 7: 177–188.
- 626 [39] Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane 627 Handbook for Systematic Reviews of Interventions, 628 https://training.cochrane.org/handbook/current (accessed 12 June 2024).

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

- 629 [40] Moy FM, Lim ERJ, Hairi NN, Bulgiba A. Depression and its associated factors 630 among COVID-19 survivors in a middle income country. 2022; 631 2022.12.15.22283550.
- 632 [41] Gaur R, Asthana S, Yadav R, Ghuleliya R, Kumar D, Akhtar M, et al. Assessment 633 of Physical Disability After Three Months in Patients Recovered From COVID-634 19: A Cross-Sectional Study. *Cureus*; 14: e21618.
- 635 [42] Farhanah N, Charles Budiman, Muchlis Achsan Udji Sofro, Budi Riyanto, Suharyo 636 Hadisaputro, Muhammad Hussein Gasem. The Persistent Symptoms and 637 Decreased Quality of Life of COVID-19 Patients (A 3-month Follow-up after 638 Discharge) | Open Access Macedonian Journal of Medical Sciences, 639 https://oamjms.eu/index.php/mjms/article/view/9755 (2024, accessed 9 June 640 2024).
- 641 [43] Miyazato Y, Tsuzuki S, Morioka S, Terada M, Kutsuna S, Saito S, et al. Factors 642 associated with development and persistence of post-COVID conditions: A cross-643 sectional study. *J Infect Chemother* 2022; 28: 1242–1248.
- 644 [44] Alkwai HM, Khalifa AM, Ahmed AM, Alnajib AM, Alshammari KA, Alrashidi 645 MM, et al. Persistence of COVID-19 symptoms beyond 3 months and the delayed 646 return to the usual state of health in Saudi Arabia: A cross-sectional study. *SAGE*  647 *Open Med* 2022; 10: 20503121221129918.
- 648 [45] Sørensen AIV, Spiliopoulos L, Bager P, Nielsen NM, Hansen JV, Koch A, et al. A 649 nationwide questionnaire study of post-acute symptoms and health problems after 650 SARS-CoV-2 infection in Denmark. *Nat Commun* 2022; 13: 4213.
- 651 [46] van Wijhe M, Fogh K, Ethelberg S, Karmark Iversen K, Nielsen H, Østergaard L, 652 et al. Persistent Symptoms and Sequelae After Severe Acute Respiratory Syndrome 653 Coronavirus 2 Infection Not Requiring Hospitalization: Results From Testing 654 Denmark, a Danish Cross-sectional Survey. *Open Forum Infect Dis* 2022; 10: 655 ofac679.
- 656 [47] Whitaker M, Elliott J, Chadeau-Hyam M, Riley S, Darzi A, Cooke G, et al. 657 Persistent COVID-19 symptoms in a community study of 606,434 people in 658 England. *Nat Commun* 2022; 13: 1957.
- 659 [48] Bungenberg J, Humkamp K, Hohenfeld C, Rust MI, Ermis U, Dreher M, et al. 660 Long COVID-19: Objectifying most self-reported neurological symptoms. *Ann*  661 *Clin Transl Neurol* 2022; 9: 141–154.
- 662 [49] Vassalini P, Serra R, Tarsitani L, Koukopoulos AE, Borrazzo C, Alessi F, et al. 663 Depressive Symptoms among Individuals Hospitalized with COVID-19: Three-664 Month Follow-Up. *Brain Sci* 2021; 11: 1175.
- 665 [50] Chudzik M, Lewek J, Kapusta J, Banach M, Jankowski P, Bielecka-Dabrowa A. 666 Predictors of Long COVID in Patients without Comorbidities: Data from the Polish 667 Long-COVID Cardiovascular (PoLoCOV-CVD) Study. *J Clin Med* 2022; 11: 668 4980.

- 669 [51] Fernández‐de‐las‐Peñas C, Torres‐Macho J, Elvira‐Martínez CM, 670 Molina‐Trigueros LJ, Sebastián‐Viana T, Hernández‐Barrera V. Obesity is 671 associated with a greater number of long‐term post‐COVID symptoms and poor 672 sleep quality: A multicentre case‐control study. *Int J Clin Pract* 2021; 75: e14917.
- 673 [52] Desgranges F, Tadini E, Munting A, Regina J, Filippidis P, Viala B, et al. 674 Post‑COVID‑19 Syndrome in Outpatients: a Cohort Study. *J Gen Intern Med* 2022; 675 37: 1943–1952.
- 676 [53] Blümel JE, Vallejo MS, Bencosme A, Calle A, Dextre M, Díaz K, et al. Post-677 COVID-19 syndrome in a sample of climacteric women living in Latin America. 678 *Menopause N Y N* 2023; 30: 165–173.
- 679 [54] Carter SJ, Baranauskas MN, Raglin JS, Pescosolido BA, Perry BL. Functional 680 Status, Mood State, and Physical Activity Among Women With Post-Acute 681 COVID-19 Syndrome. *Int J Public Health* 2022; 67: 1604589.
- 682 [55] Epsi NJ, Chenoweth JG, Blair PW, Lindholm DA, Ganesan A, Lalani T, et al. 683 Precision Symptom Phenotyping Identifies Early Clinical and Proteomic 684 Predictors of Distinct COVID-19 Sequelae. *J Infect Dis* 2024; jiae318.
- 685 [56] Global Burden of Disease Long COVID Collaborators, Wulf Hanson S, Abbafati 686 C, Aerts JG, Al-Aly Z, Ashbaugh C, et al. Estimated Global Proportions of 687 Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters 688 Following Symptomatic COVID-19 in 2020 and 2021. *JAMA* 2022; 328: 1604– 689 1615.
- 690 [57] Lledó GM, Sellares J, Brotons C, Sans M, Antón JD, Blanco J, et al. Post-acute 691 COVID-19 syndrome: a new tsunami requiring a universal case definition. *Clin*  692 *Microbiol Infect* 2022; 28: 315–318.
- 693 [58] Quan M, Wang X, Gong M, Wang Q, Li Y, Jia J. Post-COVID cognitive 694 dysfunction: current status and research recommendations for high risk population. 695 *Lancet Reg Health – West Pac*; 38. Epub ahead of print 1 September 2023. DOI: 696 10.1016/j.lanwpc.2023.100836.
- 697 [59] Mansell V, Dykgraaf SH, Kidd M, Goodyear-Smith F. Long COVID and older 698 people. *Lancet Healthy Longev* 2022; 3: e849–e854.
- 699 [60] Wilk P, Stranges S, Cuschieri S. Does sex modify the effect of pre-pandemic body 700 mass index on the risk of Long COVID? Evidence from the longitudinal analysis 701 of the Survey of Health, Ageing and Retirement in Europe. *Int J Obes 2005* 2024; 702 48: 821–829.
- 703 [61] Tana C, Giamberardino MA, Martelletti P. Long COVID and especially headache 704 syndromes. *Curr Opin Neurol* 2023; 36: 168.
- 705 [62] Melamed OC, Selby P, Taylor VH. Mental Health and Obesity During the COVID-706 19 Pandemic. *Curr Obes Rep* 2022; 11: 23–31.

#### It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

- 707 [63] Avila C, Holloway AC, Hahn MK, Morrison KM, Restivo M, Anglin R, et al. An 708 Overview of Links Between Obesity and Mental Health. *Curr Obes Rep* 2015; 4: 709 303–310.
- 710 [64] Contreras-Rodriguez O, Solanas M, Escorihuela RM. Dissecting ultra-processed 711 foods and drinks: Do they have a potential to impact the brain? *Rev Endocr Metab*  712 *Disord* 2022; 23: 697–717.
- 713 [65] Gunes-Bayir A, Tandogan Z, Gedik-Toker Ö, Yabaci-Tak A, Dadak A. A 714 Comparison Study of Nutritional Assessment, Diet and Physical Activity Habits, 715 Lifestyle and Socio-Demographic Characteristics in Individuals with and without 716 Dizziness/Vertigo. *Nutrients* 2023; 15: 4055.
- 717 [66] Neuhauser HK. The epidemiology of dizziness and vertigo. *Handb Clin Neurol* 718 2016; 137: 67–82.
- 719 [67] Hassan NM, Salim HS, Amaran S, Yunus NI, Yusof NA, Daud N, et al. Prevalence 720 of mental health problems among children with long COVID: A systematic review 721 and meta-analysis. *PLOS ONE* 2023; 18: e0282538.
- 722 [68] Bourmistrova NW, Solomon T, Braude P, Strawbridge R, Carter B. Long-term 723 effects of COVID-19 on mental health: A systematic review. *J Affect Disord* 2022; 724 299: 118–125.
- 725 [69] Staples LG, Nielssen O, Dear BF, Bisby MA, Fisher A, Kayrouz R, et al. 726 Prevalence and Predictors of Long COVID in Patients Accessing a National Digital 727 Mental Health Service. *Int J Environ Res Public Health* 2023; 20: 6756.
- 728 [70] van der Feltz-Cornelis C, Turk F, Sweetman J, Khunti K, Gabbay M, Shepherd J, 729 et al. Prevalence of mental health conditions and brain fog in people with long 730 COVID: A systematic review and meta-analysis. *Gen Hosp Psychiatry* 2024; 88: 731 10–22.
- 732 [71] Amiri S, Behnezhad S, Nadinlui KB. Body Mass Index (BMI) and risk of 733 depression in adults: A systematic review and meta-analysis of longitudinal 734 studies. *Obes Med* 2018; 12: 1–12.
- 735 [72] Aminian A, Bena J, Pantalone KM, Burguera B. Association of obesity with 736 postacute sequelae of COVID-19. *Diabetes Obes Metab* 2021; 23: 2183–2188.
- 737 [73] N S, Ib M, Jjv M. Obesity Is a Risk Factor for Severe COVID-19 Infection: 738 Multiple Potential Mechanisms. *Circulation*; 142. Epub ahead of print 7 July 2020. 739 DOI: 10.1161/CIRCULATIONAHA.120.047659.
- 740 [74] McNeill JN, Lau ES, Paniagua SM, Liu EE, Wang JK, Bassett IV, et al. The role 741 of obesity in inflammatory markers in COVID-19 patients. *Obes Res Clin Pract* 742 2021; 15: 96–99.
- 743 [75] N A, My K, Pb M, Se P. Causal Inference for Genetic Obesity, Cardiometabolic 744 Profile and COVID-19 Susceptibility: A Mendelian Randomization Study. *Front*  745 *Genet*; 11. Epub ahead of print 11 November 2020. DOI: 746 10.3389/fgene.2020.586308.

#### It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

- 747 [76] Fernández-de-las-Peñas C, Rodríguez-Jiménez J, Cancela-Cilleruelo I, Guerrero-748 Peral A, Martín-Guerrero JD, García-Azorín D, et al. Post–COVID-19 Symptoms 749 2 Years After SARS-CoV-2 Infection Among Hospitalized vs Nonhospitalized 750 Patients. *JAMA Netw Open* 2022; 5: e2242106.
- 751 [77] Hlatshwako TG, Shah SJ, Kosana P, Adebayo E, Hendriks J, Larsson EC, et al. 752 Online health survey research during COVID-19. *Lancet Digit Health* 2021; 3: 753 e76–e77.
- 754 [78] Thaweethai T, Jolley SE, Karlson EW, Levitan EB, Levy B, McComsey GA, et al. 755 Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection. 756 *JAMA* 2023; 329: 1934–1946.
- 757 [79] Burns G. Newcastle Post-COVID Syndrome Follow Up Screening Questionnaire, 758 https://postcovidsyndromebsol.nhs.uk/images/Content/ 759 Newcastle\_post\_Covid\_Screening\_Tool.pdf. (accessed 12 July 2024).
- 760 [80] Zhang X, Ha S, Lau HC-H, Yu J. Excess body weight: Novel insights into its roles 761 in obesity comorbidities. *Semin Cancer Biol* 2023; 92: 16–27.

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.11.20.24317635;](https://doi.org/10.1101/2024.11.20.24317635) this version posted November 20, 2024. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante

#### It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

## **Supporting Information**

- 
- **S1 Table. Database search strategy.**
- **S2 Table. Frequency of Post-COVID Condition neuropsychiatric symptoms of**
- **included studies that did not test for statistical differences according to nutritional**
- **status.** Excess weight group (BMI ≥ 25kg/m<sup>2</sup> ); NW: Normal Weight group (BMI < 25kg/m<sup>2</sup> ); Obesity
- 770 group  $(BMI \geq 30 \text{kg/m}^2)$ ; NOb: Non-obesity group  $(BMI \leq 30 \text{kg/m}^2)$ .
- **S1 Fig 1a: Forest-plots of excess weight and neuropsychiatric symptoms (non-**
- **significantly associations).**
- **S1 Fig 1b. Forest-plots of obesity and neurological and neuropsychiatric symptoms**
- **(non-significantly associations)**
- **S2 Fig 2. Forest-plot of the association of excess weight and the risk of neurological**
- **and neuropsychiatric symptoms.**
- **S3 Fig 3. Traffic light plots of risk of bias of included studies that reported the risk**
- **of developing neuro-symptoms assessed by Robbins-e tool.**
- **S3 Table 3. Assessment of the overall certainty of the evidence for studies thar**
- **compared the frequency of PCC neurological and neuropsychiatric symptoms**
- **among individuals with obesity and control groups**



## Random-effects DerSimonian-Laird model



## Random-effects REML model<br>(c) Headache



# Figure 3a

#### (d) Memory issues  $RR$ Weight Excess weight Normal weight Symptom No symptom  $(%)$ Study Symptom No symptom with 95% CI 3  $2.42$  [ 0.66, 8.89] 29 174 1.19 Alkwai, H.M. et al., 2022 7 Blümel, J.E. et al., 2022 158 134  $\overline{7}$ 5 1.18 [0.38, 3.63] 1.58 4,256 Whitaker, M. et al., 2022 553 6,291 255 1.43 [1.24, 1.65] 97.23 1.43 [ 1.24, 1.65] Overall Heterogeneity:  $\tau^2$  = 0.00,  $I^2$  = 0.00%,  $H^2$  = 1.00 Test of  $\theta_i = \theta_j$ : Q(2) = 0.75, p = 0.69 Test of  $\theta = 0$ :  $z = 4.99$ ,  $p = 0.00$  $0.5$  $\overline{2}$ 8 1 4

Random-effects DerSimonian-Laird model

## (e) Numbness



## Random-effects DerSimonian-Laird model

## (f) Taste disorder





Random-effects DerSimonian-Laird model

Figure 3b

## (a) Headache



## Random-effects REML model

#### (b) Memory issues Obesity Non-obesity **RR** Weight Symptom No symptom Symptom No symptom  $(% )$ with 95% CI Study Blümel, J.E. et al., 2022  $1.28$  [0.29, 5.65] 2 39 10 253 0.87 Bungenberg, J. et al., 2022 1.57 [1.06, 2.31] 12.12 6 1 24 29 . Fernández-de-las-Peñas, C. et al., 2021 72 1.23 [0.70, 2.17] 26 150 5.83 16 Whitaker, M. et al., 2022 2,531 821 1.09 [0.96, 1.24] 81.18 285 8,016 1.15 [1.00, 1.32] Overall Heterogeneity:  $t^2 = 0.00$ ,  $I^2 = 4.25\%$ ,  $H^2 = 1.04$ Test of  $\theta_1 = \theta_1$ : Q(3) = 3.13, p = 0.37 Test of  $\theta = 0$ :  $z = 1.95$ ,  $p = 0.05$  $0.5$ 1  $\overline{2}$ 4

### Random-effects DerSimonian-Laird model



Random-effects DerSimonian-Laird model

# Figure 4a



## Random-effects DerSimonian-Laird model



## Random-effects DerSimonian-Laird model



Random-effects DerSimonian-Laird model

Figure 4b



## Figure 5



Figure 1



## Figure 2